Analyst Ratings for Agomab Therapeutics (AGMB)
AGMB Rating Summary
AGMB Price Target Summary
- Highest: $60.00 (Piper Sandler)
- Lowest: $28.00 (Morgan Stanley)
- Average: $37.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$37.50 (+177%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/25/2026 | Piper Sandler | Yasmeen Rahimi | New Coverage | Overweight (N/A) |
60.00 (N/A) |
13.25 (13.54) |
2.19% | Details |
| 8/19/2026 | Cantor Fitzgerald | Yanni Souroutzidis | New Coverage | Overweight (N/A) |
N/A (N/A) |
13.73 (13.54) |
-1.38% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
